These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16100159)

  • 1. Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension.
    Shen J; He B; Wang B
    Chest; 2005 Aug; 128(2):714-9. PubMed ID: 16100159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of prostaglandin infusion in severe heart failure: preliminary clinical experience of repetitive administration.
    Serra W; Musiari L; Ardissino D; Gherli T; Montanari A
    Int J Cardiol; 2011 Jan; 146(1):e10-5. PubMed ID: 19176262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E1 increases the blood flow rate of saphenous vein grafts in patients undergoing off-pump coronary artery bypass grafting.
    Zhao L; Lu J; Wang C; Zhao W; Qing E; Ma J
    J Cardiothorac Vasc Anesth; 2013 Dec; 27(6):1208-11. PubMed ID: 24090805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful weaning from cardiopulmonary bypass with central venous prostaglandin E1 and left atrial norepinephrine infusion in patients with acute pulmonary hypertension.
    Tritapepe L; Voci P; Cogliati AA; Pasotti E; Papalia U; Menichetti A
    Crit Care Med; 1999 Oct; 27(10):2180-3. PubMed ID: 10548203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
    Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hemodynamic effects of prostaglandin E1 in patients with congenital heart disease and pulmonary hypertension].
    Pan S; Xiao M; Liu Y
    Zhonghua Wai Ke Za Zhi; 1996 May; 34(5):276-9. PubMed ID: 9387702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates.
    Radovancevic B; Vrtovec B; Thomas CD; Croitoru M; Myers TJ; Radovancevic R; Khan T; Massin EK; Frazier OH
    J Heart Lung Transplant; 2005 Jun; 24(6):690-5. PubMed ID: 15949728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery.
    Schmid ER; Bürki C; Engel MH; Schmidlin D; Tornic M; Seifert B
    Anesth Analg; 1999 Nov; 89(5):1108-15. PubMed ID: 10553820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study.
    von Scheidt W; Costard-Jaeckle A; Stempfle HU; Deng MC; Schwaab B; Haaff B; Naegele H; Mohacsi P; Trautnitz M;
    J Heart Lung Transplant; 2006 Sep; 25(9):1070-6. PubMed ID: 16962468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of different dosage of PGE1 in pulmonary arterial hypertension].
    Guo ZH; Ye YQ; Jing BW
    Zhonghua Nei Ke Za Zhi; 1993 Sep; 32(9):591-3. PubMed ID: 8112140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of prostaglandin E1 on pulmonary arterial hypertension following corrective surgery for congenital heart disease.
    Dong MF; Ma ZS; Ma SJ; Chai SD; Tang PZ; Yao DK; Wang L
    J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):303-7. PubMed ID: 22203134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of the vasodilator effects of prostaglandin E1 in patients with pulmonary hypertension after mitral valve replacement and with adult respiratory distress syndrome.
    Kunimoto F; Arai K; Isa Y; Koyano T; Kadoi Y; Saito S; Goto F
    Anesth Analg; 1997 Sep; 85(3):507-13. PubMed ID: 9296401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of intravenous administration of lipo-prostaglandin E1 on the ischemic gastric tube in pigs.
    Tobari S; Ikeda Y; Takami H
    J Surg Res; 2005 Nov; 129(1):79-84. PubMed ID: 16087193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of adenosine versus iloprost by acute vasodilator test in patients of pulmonary arterial hypertension complicated with connective tissue diseases].
    Tian Z; Chen TB; Fang Q; Zeng XF; Liu YT; Li MT; Jiang XC; Gao P; Cheng KA; Wang Q
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2099-102. PubMed ID: 20058611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside.
    Kieler-Jensen N; Lundin S; Ricksten SE
    J Heart Lung Transplant; 1995; 14(3):436-43. PubMed ID: 7654728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease.
    Benza RL; Rayburn BK; Tallaj JA; Coffey CS; Pinderski LJ; Pamoukian SV; Bourge RC
    Chest; 2006 Apr; 129(4):1009-15. PubMed ID: 16608951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of continuous intravenous prostaglandin E 1 against pulmonary hypertension].
    Satomi K; Satoh T; Kyotani S; Fukushima S; Okano Y; Nakanishi N; Kunieda T
    Nihon Kokyuki Gakkai Zasshi; 1998 May; 36(5):421-7. PubMed ID: 9742857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The acute effects of inhaled iloprost on hemodynamics and oxygenation in chronic thromboembolic pulmonary hypertension].
    Luo L; Yang YH; Cui N; Xie WM; Zhai ZG; Ma ZH; Wang C
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2103-5. PubMed ID: 20058612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy is required for management of pulmonary arterial hypertension after defect closure in adult patients with atrial septal defect and associated pulmonary arterial hypertension.
    Fujino T; Yao A; Hatano M; Inaba T; Muraoka H; Minatsuki S; Imamura T; Maki H; Kinugawa K; Ono M; Nagai R; Komuro I
    Int Heart J; 2015; 56(1):86-93. PubMed ID: 25742945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension.
    Bajwa AA; Qureshi T; Shujaat A; Seeram V; Jones LM; Al-Saffar F; Cury JD
    J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):395-400. PubMed ID: 25613465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.